fluorouracil
fluorouracil: 86 clinical trials tracked.
fluorouracil evidence translation
What we can confirm
86 tracked trials
What it means
What to watch
Prepared research question
What is verified about fluorouracil, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 9 study sponsors
Related indications
Clinical Trial Registry Records (86)showing 10 most recent
A Phase 1/2 Trial of Chemoradiotherapy With 5-Fluorouracil and Maintenance Chemotherapy for High-Risk Posterior Fossa Ependymoma
Primary endpoint: Occurrence of dose limiting toxicity chemoradiotherapy (DLT) (phase 1)
A Randomized, Open-label, Phase 3 Trial of Petosemtamab + FOLFIRI/mFOLFOX6 Versus Cetuximab or Bevacizumab + FOLFIRI/mFOLFOX6 as Second-line Treatment in Participants With RAS and BRAF Wild-type, Recurrent, Unresectable or Metastatic Colorectal Cancer
Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR)
Investigation of Mitomycin C PIPAC - FOLFIRI Combination for Unresectable Appendiceal or Colorectal Peritoneal Metastases Treatment (IMPACT): A Multicenter, Randomized, Open-Label, Phase 3 Trial
Primary endpoint: Overall survival (OS)
A Phase 2 Open-Label Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Pembrolizumab as First-Line Treatment in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Primary endpoint: Number of Participants with Adverse Events (AE)s
A Phase I Clinical Trial of Ivonescimab and ADG126, Alone, and in Combination With 5-FU/LV or FOLFIRI in MSS Advanced/Metastatic Colorectal Cancer
Primary endpoint: Incidence of dose limiting toxicities
AACR Adaptive Biomarker-Driven Organ Preservation Trial In Gastroesophageal Adenocarcinomas (AACR-ADOPT-GEA)
Primary endpoint: Pathological Complete Response (pathCR) Rate (Stage I).
Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Primary endpoint: Overall survival (OS)
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
Primary endpoint: Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
Primary endpoint: Number of Participants With Adverse Events (AEs)
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288
Primary endpoint: Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1